Ben Comer

Pittsburgh

Chief Editor at Life Science Leader

Chief Editor at Life Science Leader

Featured in: Favicon

lifescienceleader.com Favicon

informa.com Favicon

mmm-online.com Favicon

bioprocessonline.com Favicon

medtech.pharmaintelligence.informa.com

Articles

Amgen's Ian Thompson On Leadership And A Global Mindset

2 weeks ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Riding for the British Cycling team was a foundational experience for Ian Thompson, SVP and general manager of U.S. business operations at Amgen. During a recent conversation about his 16-year tenure at Amgen, and what the future holds for one of biotech’s biggest success stories, Thompson consistently tied his approach to management and business strategy to lessons learned from cycling — uphill and down.
Companies To Watch: Imunon

3 weeks ago | lifescienceleader.com | Ben Comer

Article | March 31, 2025 Source: Life Science Leader By Ben Comer, Chief Editor, Life Science Leader Using targeted therapy to transform the standard of care in advanced ovarian cancer Snapshot With the recent sign-off from the FDA on protocols for a pivotal Phase 3 trial of IMNN-001 in advanced ovarian cancer, Imunon is poised to bring its IL-12 DNA plasmid vector (encased in a nanoparticle delivery system) into late-stage clinical trials.
A CEO With A General Counsel's Perspective

1 month ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Should aspiring biopharmaceutical leaders focus on deep specialization and expertise in a singular area, or seek new and variable experiences across different parts of the business, developing a versatile skillset that can plug and play into leadership roles as needed?
FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance

2 months ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Over the last 15 years, biopharmaceutical compliance departments, and chief compliance officers, have been better resourced, with more direct reporting lines to company leadership, than ever before. A big part of that is thanks to the many Corporate Integrity Agreements (CIAs) companies entered into with government agencies in the late 2000s and up through the present (for background, see my 2013 article in Pharmaceutical Executive).
Where Are They Now? Tarsus Pharmaceuticals

2 months ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Then: In the May 2023 issue of Life Science Leader, Bobak Azamian, MD, Ph.D., cofounder and CEO of Tarsus Pharmaceuticals, talked about the company’s formation in 2016, and the decision to focus on the eyelid as a drug target, and on demodex blepharitis — an inflammatory condition caused by an overabundance of demodex mites — as a specific condition to treat.
Day One Bio Aims To Shorten the Time Gap On Cancer Treatments For Kids

2 months ago | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader One of the biggest incentives for developing new therapies for rare pediatric cancers is the FDA’s rare pediatric disease Priority Review Voucher (PRV) program. If a drug in development meets the criteria for a PRV, the sponsor company, upon FDA approval, receives a PRV that can be redeemed for FDA priority review of a different pipeline product, or can be sold to another company.
01.11.25 -- Life Science Leader Best Of December

Jan 11, 2025 | lifescienceleader.com | Blandine Lacroix |Ben Comer

DECEMBER'S BEST FEATURED EDITORIALThe Fork In The Road: Personal Decisions That Change Our Career TrajectoryNovo Nordisk SVP Blandine Lacroix shares her career story and discusses the importance of prioritizing your own personal needs, and the personal needs of others, in navigating a professional career. What Will The Incoming Trump Administration Mean For Drug Patents?
Where Are They Now? Teva Pharmaceuticals

Nov 28, 2024 | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Then: In an article published in the October 2013 issue of Life Science Leader, former executive editor Wayne Koberstein spoke with Teva’s then CEO Jeremy Levin about the company’s strategy to bridge the divide between follow-on generics and innovator branded products. The company’s future, Levin said, would depend on producing “high-value generics” and new drugs in CNS, respiratory, and other therapeutic areas.
FDA's Psychedelic Reckoning

Nov 26, 2024 | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions.
Companies To Watch: Terns Pharmaceuticals

Nov 25, 2024 | lifescienceleader.com | Ben Comer

By Ben Comer, Chief Editor, Life Science Leader Developing small molecules for cancer and obesity Snapshot What is better than first to market? Best to market, says Terns Pharmaceuticals CEO Amy Burroughs, an executive with a diverse, 25-year career in life sciences who joined Terns Pharmaceuticals as CEO in February 2024.